%0 Journal Article
%A Paz-Ares, L
%A Spira, A
%A Raben, D
%A Planchard, D
%A Cho, B C
%A Özgüroğlu, M
%A Daniel, D
%A Villegas, A
%A Vicente, D
%A Hui, R
%A Murakami, S
%A Spigel, D
%A Senan, S
%A Langer, C J
%A Perez, B A
%A Boothman, A-M
%A Broadhurst, H
%A Wadsworth, C
%A Dennis, P A
%A Antonia, S J
%A Faivre-Finn, C
%T Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
%D 2020
%U http://hdl.handle.net/10668/15280
%X In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%,  PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TC
%K PACIFIC
%K PD-L1 expression
%K durvalumab
%K immunotherapy
%K non-small-cell lung cancer
%K stage III
%~